CAS 1394820-69-9
:Ningetinib
Description:
Ningetinib is a small molecule inhibitor primarily studied for its potential therapeutic applications in oncology, particularly in the treatment of various cancers. It functions as a selective inhibitor of certain kinases involved in tumor growth and proliferation, which makes it a candidate for targeted cancer therapies. The compound exhibits a specific mechanism of action that disrupts signaling pathways critical for cancer cell survival and metastasis. Ningetinib is characterized by its unique chemical structure, which contributes to its biological activity and selectivity. In preclinical studies, it has shown promise in inhibiting tumor growth and enhancing the efficacy of other therapeutic agents. As with many investigational drugs, its pharmacokinetics, safety profile, and efficacy are subjects of ongoing research, and it may undergo various phases of clinical trials to establish its therapeutic potential and optimal dosing regimens. Overall, Ningetinib represents a significant area of interest in the development of novel cancer treatments.
Formula:C31H29FN4O5
Synonyms:- 1H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[[7-(2-hydroxy-2-methylpropoxy)-4-quinolinyl]oxy]phenyl]-2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-
- CT053PTSA
- Ningetinib(free base)
- CS-2653
- Ningetinib-Tosylate(free base)
- Ningetinib
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 4 products.
Ningetinib
CAS:<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Formula:C31H29FN4O5Purity:99.95% - 99.98%Color and Shape:SolidMolecular weight:556.58Ningetinib
CAS:<p>Tyrosine kinase inhibitor</p>Formula:C31H29FN4O5Purity:Min. 95%Molecular weight:556.58 g/mol
